TIRmed Pharma Appoints Two Experienced Industry Profiles to the Board – Strengthens Readiness for Clinical Phase
TIRmed Pharma, a biotechnology company developing innovative treatments for autoimmune skin diseases, has appointed Peder Walberg and Christian Krog-Jensen to its Board of Directors. The appointments come at a pivotal stage as the company intensifies preparations for the upcoming Phase Ib clinical trial of its lead drug candidate, TIR-C, targeting atopic dermatitis (eczema).
TIRmed is advancing a next-generation treatment for atopic dermatitis, designed to offer patients effective relief with fewer side effects and simpler administration. The treatment targets the root causes of the disease rather than merely alleviating symptoms. In preclinical studies, five topical applications over two weeks have resulted in up to 15 months of sustained relief.
The new board members strengthen the company’s strategic capabilities in drug development, business strategy, and investment—areas that are critical on the path toward the clinical phase.
“We are very pleased to welcome Peder Walberg and Christian Krog-Jensen to the board. Their complementary expertise in clinical development, strategic planning, and financing will be essential as we bring TIR-C into the clinic and position the company for long-term success,” says Leo Holmgren, CEO of TIRmed Pharma.
Peder Walberg was appointed following discussions with Sciety, one of TIRmed’s investors, who introduced him as a strong candidate with particular expertise in clinical and commercial development.
Peder Walberg is a licensed physician and economist, currently active as an investor and advisor in the life science sector, and a board member of Immedica Pharma AB. Walberg has a long-standing career in life science, with extensive experience in drug development and commercialization—including leading the Swedish launch of Elidel for atopic dermatitis during his time at Novartis. He has played a central role in strategic decision-making, regulatory planning, and negotiations with licensing partners and acquirers. His previous roles include key positions at Sobi, Wilson Therapeutics, Immedica Pharma AB, and Egetis Therapeutics.
“TIRmed has a strong team and a drug candidate with the potential to transform the treatment landscape for atopic dermatitis. I look forward to contributing my experience as the company moves toward clinical development and commercialization,” says Peder Walberg.
Christian Krog-Jensen is Investment Manager at Almi Invest, where he focuses on identifying and supporting promising companies in the life science sector. With a background in medicinal chemistry, he combines a strong scientific foundation with extensive experience in business development and research commercialization. He previously led the DRIVE incubator at KI Innovations, where he coached several successful startups. He is also an inventor with multiple patents and co-founder and leader in several biotech companies, moving drug candidates into clinical trials.
“There is a clear scientific rationale behind TIRmed’s approach, and I see strong potential in the company’s strategy. I’m excited to support the team in the next phase,” says Christian Krog-Jensen.
For more information, please contact:
Leo Holmgren, CEO
Phone: +46 70 049 18 42
Email: leo.holmgren@tirmedpharma.com
About TIRmed Pharma
TIRmed Pharma is a biotechnology company developing next-generation immunomodulatory therapies for autoimmune skin diseases, with an initial focus on atopic dermatitis (eczema). The company’s drug candidate, TIR-C, is a topical oligonucleotide-based treatment that regulates immune responses and targets the disease’s underlying mechanisms. Promising preclinical results support its potential to provide long-lasting relief and reduce treatment burden. Building on expertise in immunology and drug development, the company is pioneering new solutions in dermatological immunotherapy to enable more targeted and effective treatment options.
TIRmed Pharma is headquartered in Stockholm, Sweden. For more information, visit tirmedpharma.com and follow TIRmed on LinkedIn.
Tags:
